No Data
No Data
No Data
No Data
No Data
Replimune Group Provides Interim Results for Skin Cancer Therapy
Replimune Group (REPL) said Sunday that a phase 1/2 clinical trial of its RP1 monotherapy for skin cancer has initially showed an overall response rate of 34.8%. The interim overall response rate come
MT NewswiresApr 8 05:42 ET
Replimune Group Presented The Interim Results From The ARTACUS Clinical Trial Of RP1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers At AACR 2024
In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partia
BenzingaApr 8 02:21 ET
Interim Results From the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients With Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, by Michael R. Midgen, M.D., of the University of Texas MD Anderson Cancer Center during an oral session at the AACR 2024 Annual Meeting in San Diego.
GlobeNewswireApr 7 17:00 ET
Analysts Are Bullish on Top Healthcare Stocks: Replimune Group (REPL), Merck & Company (MRK)
TipRanksMar 27 03:40 ET
Replimune Names Sushil Patel as CEO in Broader Shakeup
By Will Feuer Replimune Group, a clinical-stage biotechnology company, named Sushil Patel as its next chief executive officer, succeeding Philip Astley-Sparke, who will become executive chairman. Th
WSJMar 26 07:44 ET
Replimune Group Announces CEO Transition
Seeking AlphaMar 26 07:37 ET
No Data
No Data